Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome | Zendy

Thomas F. Patterson | Zendy; Helen W. Boucher | Zendy; Raoul Herbrecht | Zendy; David W. Denning | Zendy; Olivier Lortholary | Zendy; Patricia Ribaud | Zendy; R H Rubin | Zendy; John R. Wingard | Zendy; Ben E. dePauw | Zendy; Haran T. Schlamm | Zendy; Peter F. Troke | Zendy; John E. Bennett | Zendy

Open Access

Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome

Author(s) -

Thomas F. Patterson,

Helen W. Boucher,

Raoul Herbrecht,

David W. Denning,

Olivier Lortholary,

Patricia Ribaud,

R H Rubin,

John R. Wingard,

Ben E. dePauw,

Haran T. Schlamm,

Peter F. Troke,

John E. Bennett

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/497126

Subject(s) - voriconazole , amphotericin b deoxycholate , amphotericin b , medicine , aspergillosis , randomized controlled trial , mycosis , gastroenterology , surgery , antifungal , caspofungin , immunology , dermatology

In a previous randomized trial of voriconazole versus amphotericin B deoxycholate for primary therapy of invasive aspergillosis, voriconazole demonstrated superior efficacy and better survival. In that trial, treatment with voriconazole or amphotericin B deoxycholate could be followed with other licensed antifungal therapies (OLAT). Here, we report the impact of OLAT on the outcome of patients with invasive aspergillosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research